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CC BY-NC-ND license.Summary Acute exacerbations (AE) can be recurrent problems for patients with moderate-
to-severe chronic obstructive pulmonary disease (COPD) increasing morbidity and mortality.
Evidence suggests that 50% of acute exacerbations involve bacteria requiring treatment
with an antibiotic which should have high activity against the causative pathogens. However,
sputum analysis is not a pre-requisite for antibiotic prescription in outpatients as results are
delayed and patients are likely to be colonised with bacteria in the stable state. Clinicians
rely on the clinical symptoms, sputum appearance and the patient’s medical history to
decide if an AE-COPD should be treated with antibiotics. This article reviews the available
data of antibiotic trials in AE-COPD. Management of frequent exacerbators is particularly
challenging for physicians. This may include antibiotic prophylaxis, especially macrolides
because of anti-inflammatory properties; though successful in reducing exacerbations, con-
cerns about resistance development remain. Inhalation of antibiotics achieves high local con-
centrations and minimal systemic exposure; therefore, it may represent an attractive
alternative for antibiotic prophylaxis in certain COPD patients. Inhaled antibiotic prophylaxis07 351 8337; fax: þ44 207 351 8338.
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498 R. Wilson et al.has been successfully used in other respiratory conditions such as non-cystic fibrosis bronchi-
ectasis which itself might be present in COPD patients who have chronic bacterial infection,
particularly with Pseudomonas aeruginosa.
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Chronic obstructive pulmonary disease (COPD) is a substan-
tial public health burden, associated with a high incidence
of morbidity and mortality and affecting 24 million people
in the USA and approximately 7% of Europeans.1e3 The pre-
dicted number of affected people in Asia Pacific region is
even higher (>55 million).4 The progressive course of
COPD is accelerated by acute exacerbations (AE-COPD),
which are episodes of worsening of symptoms, which are
the most frequent cause of hospitalisations and death
among COPD patients.5e8 Health status of hospitalised pa-
tients with severe exacerbations declines more rapidly af-
ter the second admission with risk of mortality remaining
high for approximately 90 days after every severe episode.7
Therefore, treatments that reduce exacerbation frequency
will have a significant impact on health status, survival and
reduce the economic burden of COPD.9,10
Treatment with inhaled corticosteroids, long-acting
anticholinergics or beta-agonists appears to have modest
but significant effects on preventing or reducing subse-
quent moderate and severe exacerbations in COPD pa-
tients.11e14 However, improvements in the treatment of
stable COPD are needed to further decrease exacerbations
and improve outcomes. Evidence based on sputum culture
results suggests that bacterial infection may be responsible
for around half of AE-COPD,15 with a clear relationship be-
ing demonstrated between sputum purulence and the pres-
ence of bacteria.16,17 For this reason, current guidelines
recommend acute antibiotic therapy for patients with
more severe symptoms of AE-COPD, with treatment typi-
cally lasting for 5e7 days.18e21 In particular, guidelines is-
sued by the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) and the Joint Task Force of the European
Respiratory Society and the European Society for Clinical
Microbiology and Infectious Diseases advocate antibiotic
use for those with Anthonisen type I (worsening dyspnoea
with increased sputum volume and purulence) or type II
(change in any two of these symptoms, particularly if one
of these symptoms is increase in sputum purulence) epi-
sodes,18,20,21 while the Canadian Thoracic Society suggests
that antibiotics are beneficial for severe purulent AE-
COPD (i.e. new increased expectoration of mucopurulent
sputum and dyspnoea).19 Nevertheless, while such treat-
ment has been shown to reduce the risk of subsequent ex-
acerbations, relapse is common.22 Failure may be related
to inadequate antibiotic efficacy, which through incom-
plete resolution of the initial exacerbation and persistent
bacterial infection is likely to influence risk of relapse.23e27
Indeed, confirmed bacterial eradication following antibi-
otic therapy has been shown to be associated with higher
clinical cure rates in patients with AE-COPD.28 Effective
treatment of the acute exacerbation and reducing the
risk of a subsequent bacterial exacerbation are thusimportant therapeutic goals for antimicrobial treatment
in COPD that may improve, in addition to other conven-
tional treatments (e.g. long-acting bronchodilators and
inhaled corticosteroids), the patients’ quality of life.
The rate at which exacerbations occur appears to reflect
an independent susceptibility phenotype.5,29 Furthermore,
exacerbations appear to cluster together, with some pa-
tients remaining at high risk for recurrent exacerbation
for some weeks after the initial exacerbation,5,9,30,31
possibly due to ongoing lung and systemic inflammation.32
While acquisition of new strains of respiratory pathogens
is an important mechanism underlying acute COPD exacer-
bations,33 chronic microbial colonisation of the lower respi-
ratory tract is also relevant.34e36 This colonisation is likely
to contribute to chronic inflammation and progressive loss
of lung function in COPD due to increased rate of exacer-
bations.33,35e39 Treatments aimed at reducing bacterial
colonisation, which may be regarded as chronic infection
in the presence of an inflammatory response,40 may, there-
fore, help reduce the progression of the disease. It is also
likely that the chronic inflammation in COPD compromises
innate lung defence, increasing susceptibility to acute
infection and thus the risk of subsequent exacerbations.
Identifying the sub-group of COPD patients who are subject
to this vicious cycle of chronic inflammation and infection is
challenging, though infection is signalled by the presence of
chronic purulent sputum production. High resolution CT
scan may help identify bronchiectasis, particularly in the
presence of Pseudomonas aeruginosa.41e43 In the future,
sputum biomarkers might help in management.44
Traditionally, most antibiotic clinical trials have focussed
on short-term clinical efficacy in the treatment of AE-COPD.
Recently, information has emerged on the longer-term out-
comes of acute treatment for an exacerbation (i.e. several
weeks or months after initial antimicrobial treatment), and
on the possible value of long-term antibiotic therapy as a
longer-term strategy to prevent future exacerbations.45,46
This article reviews the current evidence on the impact of
acute antibiotic treatment on the long-term outcomes in
COPD, explores the potential for the use of prophylactic an-
tibiotics and discusses the possible role of inhaled antibiotics
in patients with the condition.
Impact of acute antibiotic treatment on long-
term outcome in AE-COPD
Clarifying the precise benefit of antibiotics in AE-COPD
patients is challenging since few placebo-controlled clinical
trials have been conducted in this population. Older studies,
however, show that patients with more symptomatic exacer-
bations, such as those with increased dyspnoea, sputum
productionandpurulence [Anthonisentype1exacerbation],18
frequent exacerbations or exacerbations requiring hospital-
isation26,47,48 derive benefit from antibiotic treatment. There
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in AE-COPD.26,27 In one study, addition of 7-day doxycycline
treatment to systemic corticosteroids in patients hospitalised
with AE-COPD, showed limited benefit from the antibiotic
treatment. The primary clinical endpoint of clinical success
on Day 30 was not met (61% vs 53%; odds ratio [OR] 1.3;
PZ 0.32), with the two arms also being equivalent for clinical
cure at Day 30.26 Although doxycycline was found to be supe-
rior to placebo in terms of clinical success (OR 1.9; PZ 0.03)
and clinical cure (OR 1.9; PZ 0.01) on Day 10 of the study,26
such treatment had no effect on lung function or systemic
inflammation (measured by change in FEV1 and serum C-reac-
tive protein, respectively, at Days 10 or 30). The authors
concluded that failure of the primary outcome may have
been due to the use of steroids, which may have limited the
benefitofantibiotics in this study.Alternatively, the lackofef-
fectmayhavebeendue to insufficient antibacterial activityof
doxycycline; indeed, the rateofbacteriological eradicationof
theoffendingpathogen in this studywasonly67%withdoxycy-
cline versus 34%with placebo, which could explain the lack of
durability of the clinical efficacy. Llor et al.27 in an outpatient
study of the efficacy of antibiotics in acute exacerbation of
mild-to-moderate COPD demonstrated that amoxicillin-
clavulanate is associated with greater clinical success
compared to placebo at the end-of-therapy visit (Days 9e11)
for those with Anthonisen type II criteria (74.1% vs 59.9%,
respectively; 95%CI of the difference inpercentageof success
3.7e24.3%). This study showedthat thereareclear short-term
benefits from antibiotics in an outpatient setting in patients
without severe disease.27
Based on these and previous studies, the short-term
benefit in terms of clinical cure or success of about 13e15%
above placebo is seen with antibiotic use. Interestingly, this
magnitude of benefit is very similar to what is seen with
systemic steroid use at exacerbation. Few studies have
addressed whether antibiotic treatments have any enduring
effects. This is due to the fact that most antibiotic studies
only include follow up for up to 21 days after the end-of-
treatment.49e54 These follow-up periods are likely to be far
too short to identify all relapses, since risk of relapse is
highest in the 8-week period after the end-of-therapy.30
The effect of a single course of acute antibiotic treatment
on longer-term outcomes has been examined in some
studies, with patients being followed for between 8 weeks
and 1 year.27,28,31,55e61 Only one of these studies27 was pla-
cebo controlled, while the remainder were antibiotic com-
parison trials. In the placebo-controlled trial by Llor et al.
discussed above, amoxicillin/clavulanate was associated
with a significantly prolonged time to the next exacerbation
during the long-term follow-up period (233 days vs 160
days; P < 0.05).27 The antibiotic comparison trials are
important also, as they demonstrate that antibiotic choice
impacts on long-term outcomes in AE-COPD, specifically
reducing clinical relapses, the need for additional antibi-
otics and prolonging the time to the next exacerbation.
However, not all studies demonstrated differences in
long-term outcomes between antibiotic treatments. Antibi-
otic comparison trials where long-term outcomes of exacer-
bations were examined are summarised in Table 1.
Comparison between these trials is difficult due to the
fact that some enrolled patients with AE-COPD, while
others involved patients with exacerbations of chronicbronchitis; patients included may, therefore, reflect
different inflammatory sub-phenotypes and varying
severity of airflow obstruction within COPD.62 The end-
points employed and the demographic characteristics of
the study populations also varied between studies. For
example, in the study reporting the longest follow-up
period of one year, patients receiving antibiotic treatment
with either levofloxacin or clarithromycin experienced a
mean exacerbation-free interval of more than 300 days.59
In a further study employing a 6-month follow-up, antibi-
otic treatment with levofloxacin or clarithromycin led to
an infection-free interval of 112 and 102 days, respec-
tively.58 The difference in exacerbation-free interval re-
sulting from levofloxacin treatment in these two studies
(300 days vs 112 days) is unclear, but may be due to the
fact that 82% of patients in the latter study had severe or
very severe COPD (forced expiratory volume in 1 s
[FEV1] < 50% predicted),
58 in contrast to only 27% of severe
patients in the former study.59
The pioneering trial in this field by Chodosh et al.60
demonstrated that ciprofloxacin achieved higher bacterio-
logical eradication rates than clarithromycin, however,
with a non-significant increase in the infection-free interval
associated with ciprofloxacin (142 vs 51 days, P Z 0.15).
The MOSAIC trial, a large study enrolling patients with sta-
ble COPD prior to an acute exacerbation, showed significant
improvement in long-term outcomes with moxifloxacin dur-
ing a 9-month follow-up period versus standard antibiotics
(amoxicillin, clarithromycin or cefuroxime-axetil)55 report-
ing delayed onset of a composite failure event (treatment
failure and/or new exacerbation and/or any further antibi-
otic treatment). In two other studies, gemifloxacin was
associated with significantly lower relapse rates in 6
months, non-significant reduction in hospitalisations
(P Z 0.059) and better health status scores at 6 months
than clarithromycin.9,31 A smaller study, conducted by
Nouira et al., was not able to show any difference in
long-term outcomes in hospitalised patients between cipro-
floxacin and trimethoprim-sulfamethoxazole.61 In the
recently published MAESTRAL study, while moxifloxacin
treatment was comparable to amoxicillin/clavulanic acid
for the primary endpoint of clinical failure at 8-weeks
post-therapy, moxifloxacin resulted in significantly lower
clinical failure and higher bacteriological eradication in a
sub-population of patients with bacterial pathogens iso-
lated from sputum at the time of exacerbation.28
The exact mechanism(s) underlying the effects of acute
antibiotic treatment on long-term outcome is (are) uncer-
tain, though eradication of the infecting bacteria causing
the exacerbation is likely to play a key role. This was best
demonstrated in the MAESTRAL study, in which in the post-
hoc assessment of a sub-group of patients with bacterial
pathogens isolated from sputum at the time of exacerba-
tion, a significant relationship was observed between
bacterial eradication at end-of-treatment (EOT) and the
rate of clinical cure at 8 weeks. This relationship was seen
both in the overall population and in moxifloxacin-treated
patients, though the correlation was not present in those
treated with amoxicillin/clavulanic acid.28 Interestingly,
the studies that have shown significant differences
between the fluoroquinolones and the comparators in
long-term outcomes have been conducted with agents
Table 1 Studies reporting long-term effects of acute oral antibiotic therapy on AE-COPD or AECB.
Study (total
number of
patients)
Study
design
Diagnosis/patient characteristics
at baseline (mean)
Treatment Endpoint Duration of
follow-up
Long-term
outcome
Chodosh et al.60
(n Z 491)
Randomised,
double-blind,
multicentre
Diagnosis: AECB
Mean age: ciprofloxacin
59 yrs; clarithromycin 60 yrs
Current smokers: ciprofloxacin
38%; clarithromycin 31%
Comorbidity: N/R
FEV1 < 50% predicted: N/R
Anthonisen type 2/3:
ciprofloxacin 21%;
clarithromycin 26%
2 Exacerbations in
previous yr: ciprofloxacin 68%;
clarithromycin 70%
14 Days
ciprofloxacin
500 mg qd vs
14 days
clarithromycin
500 mg bid
Infection-free
interval between AECB
36 Weeks  Non-significant trend towards
longer infection-free interval
for ciprofloxacin (142 vs 51
days for clarithromycin;
P Z 0.15)
 Bacteriological eradication was
significantly higher for
ciprofloxacin (91% vs 77%;
P < 0.01)
Grassi et al.56
(n Z 476)
Randomised,
open-label,
multicentre
Diagnosis: AECB
Mean age: moxifloxacin 70 yrs:
ceftriaxone 69 yrs
Current smokers: 22%
Comorbidity: N/Ra
FEV1 < 50% predicted: N/R
Exacerbations in previous yr: 3.0
5 Days
moxifloxacin
400 mg PO qd vs
7 days ceftriaxone
1 g IM qd
Clinical response
at TOC (10 d after
end-of-therapy)
6 Months  Comparable clinical success
at TOC (91% vs 89%)
 Lower relapse rate (23% vs 28%;
NS) greater cost savings (V1993
vs V2219) and lower
hospitalisation rate (1864 vs
2001) for moxifloxacin
Wilson et al.31
(n Z 712)
Randomised,
double-blind,
multicentre
Diagnosis: AECB
Mean age: gemifloxacin: 58 yrs;
clarithromycin 58 yrs
Current smokers: gemifloxacin:
44%; clarithromycin 47%
Mean duration of chronic
bronchitis: gemifloxacin: 13 yrs;
clarithromycin 12 yrs
Comorbidity: N/R
4 Exacerbations in previous yr:
gemifloxacin: 10%;
clarithromycin 11%
5 Days gemifloxacin
320 mg qd vs 7 days
clarithromycin
500 mg bid
Long-term effect
of therapy on AECB
recurrence requiring
additional antibiotic
therapy after resolution
of the initial episode
26 Weeks  Similar clinical
success rates between
treatments after 2e3
weeks (85.4% vs 84.6%
 Significantly more
gemifloxacin patients
remained free of
AECB recurrence
(71% vs 59%; P Z 0.016)
 Fewer hospitalisations for
gemifloxacin vs clarithromycin
patients (2.3% vs 6.3%;
P Z 0.059 [NS])
Lode et al.59
(n Z 511)
Randomised,
double-blind,
multicentre
Diagnosis: AE-COPD
Mean age: levofloxacin 60 yrs;
clarithromycin 60 yrs
Current smokers: levofloxacin
34%; clarithromycin 33%
CVD comorbidity: levofloxacin
36%; clarithromycin 39%
FEV1 % predicted: levofloxacin
58%; clarithromycin 59%
Exacerbations in previous yr: 2/yr
7 Days levofloxacin
500 mg qd vs 10 days
clarithromycin
250 mg bid
Exacerbation-free
interval at 1 year
1 Year  Exacerbation-free interval
at 1 yr was similar in the two
groups (300 vs 350 days)
 Significantly higher
bacteriological eradication
rate for levofloxacin
(96% vs 81.7%; P < 0.0001)
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Wilson et al.55
(n Z 1935)
Randomised,
double-blind,
multicentre
Diagnosis: AECB
Mean age: moxifloxacin 64 yrs;
comparator 63 yrs
Current smokers: moxifloxacin
41%; comparator 46%
Cardiopulmonary disease:
moxifloxacin 15%; comparator
14%
FEV1 < 50% predicted:
moxifloxacin 42%; comparator
42%
4 Exacerbations in previous yr:
moxifloxacin 27%;
comparator 28%
5 Days moxifloxacin
400 mg qd vs 7 days
amoxicillin 500 mg tid,
or clarithromycin
500 mg bid or
cefuroxime-axetil
250 mg bid
Primary: clinical
success 7e10 d after therapy.
Secondary: clinical
cure (return to
pre-exacerbation
status), further
antimicrobial use,
time to next AECB,
and bacteriologic success
9 Months  Similar clinical success
rates between treatments
(88% vs 83%)
 Superior clinical cure (71% vs
63%), clinical success in pts
with bacteriologically confirmed
AECB (88% vs 78%) and
bacteriological success (77% vs
68%) for moxifloxacin
 Longer mean time to
next exacerbation for
moxifloxacin
(132.8 vs 118 days;
P Z 0.03)
 Less frequent
occurrence of failure,
new exacerbation, or
need for antibiotics for
moxifloxacin for up to
5 months (P Z 0.03).
Ruiz-Gonzales
et al.58
(n Z 116)
Randomised,
open-label
Diagnosis: AE-COPD
Mean age: levofloxacin 64 yrs;
standard 62 yrs
Current smokers: N/R
Comorbidity: levofloxacin 58%;
standard 63%
Severe COPDb: levofloxacin
51%; standard 58%
Exacerbations in
previous yr: N/R
10 Days levofloxacin
500 mg qd vs 10 days
clarithromycin
500 mg bid,
cefuroxime-
axetil 500 mg bid or
amoxicillin/clavulanate
875/125 mg tid
Long-term outcome
(including mortality,
no. of exacerbations,
hospitalisation,
infection-free interval
time) at 6 months
6 Months  Similar numbers of
exacerbations during
follow-up (33 vs 41) and
infection-free interval
(112 vs 102 days)
 Reduced hospitalisation
at 6 months for levofloxacin
vs standard antibiotics
(33% vs 66%; P Z 0.02)
Petitpretz et al.57
(n Z 585)
Randomised,
open-label,
multicentre,
Diagnosis: AE-COPD
Mean age: levofloxacin 64 yrs;
cefuroxime 64 yrs
Current smokers: levofloxacin
40%; cefuroxime 41%
Comorbidity: levofloxacin 41%;
cefuroxime 36%
FEV1 % predicted: levofloxacin
51%; cefuroxime 53%
Exacerbations in previous yr:
levofloxacin 3.5; cefuroxime 3.6
10 days levofloxacin
500 mg qd vs 10 days
cefuroxime 250 mg bid
Clinical cure
rate at TOC
(day 17e21)
6 Months  Similar clinical cure
rates at TOC (95% vs 94%)
 Probability of relapse
during follow-up in 25%
of pts longer for levofloxacin
(93 vs 81 days; NS)
(continued on next page)
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Table 1 (continued )
Study (total
number of
patients)
Study
design
Diagnosis/patient characteristics
at baseline (mean)
Treatment Endpoint Duration of
follow-up
Long-term
outcome
Nouira et al.61
(n Z 170)
Randomised,
double-blind,
multicentre
Diagnosis: AE-COPD
Mean age: trimethoprim-
sulfamethoxazole 68 yrs;
ciprofloxacin 67 yrs
No. of pack-yrs smoking:
trimethoprim-sulfamethoxazole
61 yrs; ciprofloxacin 56 yrs
Comorbidity: N/Ra
FEV1 ml/s: trimethoprim-
sulfamethoxazole 953;
ciprofloxacin 878
Exacerbations in previous yr:
trimethoprim-sulfamethoxazole
2.3; ciprofloxacin 2.3
10 days trimethoprim-
sulfamethoxazole
160/800 mg bid vs 10
days ciprofloxacin
750 mg bid
Primary: hospital
death and the
need for an additional
course of antibiotics
Secondary:
exacerbation-free
interval
6 Months  Combined hospital
death and additional
antibiotic prescription
rates were similar for
trimethoprim-sulfamethoxazole
and cirprofloxacin
(16.4% vs 15.3%; P Z 0.832).
 Mean exacerbation-free
interval was similar in
both treatment groups
(83 vs 79 days; P Z 0.41).
Wilson et al.28
(n Z 1492)
Randomised,
double-blind,
multicentre
Diagnosis: AE-COPD
Mean age: moxifloxacin 70 yrs;
amoxicillin/clavulanic acid 69 yrs
Current smokers: moxifloxacin
24%; amoxicillin/clavulanic
acid 23%
Comorbidity: moxifloxacin 78%;
amoxicillin/clavulanic acid 81%
FEV1 % predicted: moxifloxacin
39%; amoxicillin/clavulanic
acid 39%
Exacerbations in previous yr:
moxifloxacin 2.5; amoxicillin/
clavulanic acid 2.5
5 Days moxifloxacin
400 mg qd vs 7 days
amoxicillin/
clavulanic acid
875/125 mg bid
Clinical failure
at 8-weeks post-therapy
8 Weeks  Similar clinical failure
rates at 8 wks post-therapy
(21% vs 22%);
 Significantly lower clinical
failure for moxifloxacin in
pts with confirmed
bacterial AE-COPD
(19% vs 25%; P Z 0.016)
 Higher eradication rate
for moxifloxacin in the
sub-population of pts
with confirmed pathogens
at baseline (66% vs 59%;
P Z 0.026).
TOC, test-of-cure; AECB, acute exacerbation of chronic bronchitis; AE-COPD, acute exacerbation of chronic obstructive pulmonary disease; SGRQ, St George’s Respiratory Questionnaire;
bid, twice daily; qd, once daily; tid, three times daily; NS, not significant; N/R, not reported; CVD, cardiovascular disease; FEV1, forced expiratory volume in 1 s, PO, per os, IM,
intramuscularly.
a Patients with significant comorbid conditions were excluded.
b 30%  FEV1 < 50% predicted.
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Antibiotics for treatment and prevention of AE-COPD 503(moxifloxacin and gemifloxacin) that have better activity
against Gram-positive pathogens such as Streptococcus
pneumoniae. In contrast, initial studies with ciprofloxacin
and low-dose levofloxacin have not been able to
show improvement in long-term outcomes. While the
increased airway inflammation present during an acute
exacerbation is thought to be reduced following antibiotic
treatment,63e66 this improvement may be dependent on
bacterial eradication.25 Such incomplete resolution of
the initial exacerbation and persistent bacterial infection
appear to be important determinants of the risk of
relapse.23e26,37
Overview of clinical trials of prophylactic
antimicrobial use in AE-COPD
The concept of long-term antibiotic use comes from a
number of other chronic respiratory tract conditions in
which chronic bacterial infection occurs. The well-
established indication for the long-term use of inhaled
antibiotics is the prevention of exacerbations in cystic
fibrosis patients,67e71 and more recently in non-cystic
fibrosis bronchiectasis.72 Long-term macrolide therapy
was first shown to be of significant benefit in a predomi-
nantly Japanese respiratory disease, diffuse pan-bronchio-
litis.73 Though less well established long-term treatment
with low-dose erythromycin or clarithromycin has also
been shown to improve clinical outcome in patients with
intractable chronic sinusitis.74,75 In non-cystic fibrosis bron-
chiectasis, addition of twice-weekly azithromycin to pa-
tients’ usual medications for 6 months significantly
decreased the incidence of exacerbation and 24-h sputum
volume.76 Furthermore, long-term, low-dose erythromycin
has been shown to be effective in bronchiectasis subjects
with frequent infective exacerbations.77 More recently, 6-
month treatment with azithromycin reduced the frequency
of exacerbations in bronchiectasis patients with a history of
at least one exacerbation in the previous year, though no
improvement in quality of life was observed during the
treatment period.78
The potential role of long-term antibiotic therapy in the
management of COPD was first investigated in the 1950s
and 1960s. However, these studies were limited by small
patient numbers, use of low doses of narrow-spectrum
antibiotics and poor efficacy measurements. Concerns
regarding resistance also hindered further investigation
into the value of this approach.79 Nonetheless, new antibi-
otic formulations with improved antibacterial activity
coupled with better understanding of the pathogenesis of
COPD has led to renewed interest in the role of long-term
antibiotic use in COPD management,80 though no agents
are currently licensed for such therapy.
Review of more recent reports from the last decade
investigating the long-term use of antibiotic treatment in
COPD patients revealed a total of seven studies examining
continuous therapy45,81e86 and one employing an intermit-
tent/pulsed schedule (Table 2).46 Of the studies investi-
gating continuous therapy, all investigated long-term
macrolide therapy, with most examining treatment over a
12-month period.45,81,86 The rationale for the use of macro-
lides as maintenance therapy stems from the fact that theseagents hold immunomodulatory and anti-inflammatory ef-
fects in addition to their antibacterial properties.87 In the
first 12-month study, erythromycin therapy was found to
have beneficial effects on the prevention of exacerbations
in 55 COPD patients.81 The proportion of patients with one
or more episodes of exacerbation during the treatment
period was lower in patients treated with erythromycin
(11%) compared to the controls (56%), and significantly
more control patients than erythromycin patients were hos-
pitalised due to exacerbations (P Z 0.0007). It should be
noted, however, that this investigation was limited in that
it was an open-label study, not a randomised double-blind
placebo-controlled trial. Such a trial of erythromycin treat-
ment was subsequently shown to significantly reduce exac-
erbation frequency and median time to exacerbation in a
12-month study, though no differences between arms
were observed in FEV1 or inflammatory markers.
86 In
contrast, no reduction of exacerbations, sputum neutrophil
numbers or cytokine levels were observed following 3-
month treatment with clarithromycin versus placebo,
possibly due to the small sample size (n Z 67) and shorter
study period.82 However, significant reductions in inflamma-
tory markers and neutrophil counts were reported following
6-month treatment with azithromycin in addition to stan-
dard care in severe COPD patients83 and with erythromycin
versus placebo, respectively.84
Recently, in a large definitive study, Albert et al.45 have
investigated the use of 12-month treatment with daily azi-
thromycin in COPD patients with an increased risk of exac-
erbations (mean age 65 years, FEV1 % predicted was 39%). In
this study, addition of azithromycin to standard therapy led
to a 27% decrease in the frequency of exacerbations, an in-
crease in the median time to exacerbations (266 days vs 174
days, respectively; P < 0.001) and significantly improved
disease specific health status (St George’s Respiratory
Questionnaire [SGRQ] 2.8 vs 0.6; P Z 0.004). However,
the improvement in the SGRQ did not reach the minimal
clinically important difference. Azithromycin was also
shown to reduce exacerbations, hospitalisations, and
length of hospital stay in patients with severe COPD
(mean age 71 years, FEV1 % predicted 32%, 7.0 exacerba-
tions in previous year) in a 12-month retrospective study.85
The effect of azithromycin in this study was particularly
marked in patients with common potentially pathogenic mi-
croorganisms isolated in sputum (i.e. Haemophilus influen-
zae, S. pneumoniae or Moraxella catarrhalis), reducing
exacerbations and hospitalisations by 70% and mean hospi-
tal stay by 25 days.
Intermittent, pulsed fluoroquinolone antibiotic therapy
in COPD patients has been investigated in a study conduct-
ed by Sethi et al.46 In this study, moxifloxacin was adminis-
tered once daily for 5 days, with treatment being repeated
every 8 weeks for a total of six courses.46 The rationale for
pulsed therapy was mainly driven by the concerns about
the emergence of resistance with long-term continuous
use of antibiotics. Pulsed therapy would allow time for
the normal flora to recover and therefore potentially pre-
vent or delay the emergence of resistant strains.33
Moxifloxacin was selected for the study based on its potent
in vitro activity against the major COPD pathogens,
excellent penetration into respiratory tissues, high oral
bioavailability and proven efficacy in increasing the
Table 2 Studies investigating use of prophylactic oral antibiotics in stable COPD patients.
Study Study design Patient characteristics
at baseline (mean)
Treatment Duration of
antibiotic
treatment
Outcome Side effects
Continuous therapy
Suzuki et al.81 Randomised,
un-blinded
controlled trial
Mean age: erythromycin
69 yrs; no therapy 72 yrs
Current smokers: N/R
Comorbidity: N/Ra
FEV1 L/s: erythromycin
1.3; no therapy 1.5
Exacerbations in
previous yr: N/R
Erythromycin 200e400
mg/day (n Z 55) vs no
therapy (n Z 54)
12 months  Reduction in no. of
common colds in 1 yr
for erythromycin
(1.2 vs 4.5; P Z 0.0002)
 Fewer erythromycin
patients had 1
exacerbation (11% vs 56%)
 More control patients
were hospitalised for
exacerbations (P Z 0.0007)
Not reported
Banerjee
et al.82
Randomised,
double-blind,
controlled trial
Mean age: clarithromycin
65 yrs; placebo 68 yrs
Current smokers:
clarithromycin 45%;
placebo 64%
Comorbidity: N/Rb
FEV1 % predicted:
clarithromycin 43%;
placebo 44%
Exacerbations in
previous yr: N/Rc
Clarithromycin
500 mg/day (n Z 31)
vs placebo n Z 36)
3 months  No effect of clarithromycin
on sputum total cell or
neutrophil count or
cytokine levels
 Small reduction in the
neutrophil differential
(P Z 0.04) and neutrophil
chemotaxis
(P Z 0.058) vs placebo
GI symptoms in one
clarithromycin
patient
Seemungal
et al.86
Randomised,
double-blind,
controlled trial
Mean age: erythromycin
67 yrs; placebo 68 yrs
Current smokers:
erythromycin 51%;
placebo 45%
Comorbidity: N/Rb
FEV1 % predicted:
erythromycin 49%;
placebo 51%
3 exacerbations in
previous yr: erythromycin
36%; placebo 34%
Erythromycin
250 mg bid (n Z 53)
vs placebo (n Z 56)
12 months  Significant reduction
in exacerbation
frequency for erythromycin
vs placebo (P Z 0.006)
 Erythromycin reduced the
median time to exacerbation
(271 vs 89 days; P Z 0.02)
 No difference between
arms in FEV1 or inflammatory
markers (sputum IL-6, IL-8,
myeloperoxidase, serum
C-reactive protein
or serum IL-6)
No significant
differences between
arms
One case of
erythromycin
resistance
Blasi et al.83 Randomised,
open label study
Mean age: azithromycin
72 yrs; SC 73 yrs
Current smokers: 0%
Comorbid HTN:
azithromycin 36%; SC 46%
Comorbid CAD:
Azithromycin 500 mg
three times/week
(n Z 11) vs SC (n Z 11)
6 months  Significant reduction
in exacerbations
(P Z 0.001) and
hospitalisations (P Z 0.02)
after 3 months
azithromycin vs. SC
No serious AEs
No resistance reported
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azithromycin 27%; SC 36%
FEV1 % predicted: N/R
MRC: azithromycin 3.0; SC 2.6
Exacerbations in previous yr:
azithromycin 3.0; SC 3.1
 Significant reduction
in no. of exacerbations
during 6-month azithromycin
treatment vs 6-month follow-up
(P Z 0.016); no
difference in the SC
group (P Z 0.56)
 Reduction if inflammatory
markers e TNFa and IL-6
during azithromycin treatment
 Significant improvement in
QoL after 3 (P Z 0.006) and 6
months (P Z 0.002) azithromycin
He et al.84 Randomised,
double-blind,
controlled trial
Mean age: erythromycin
69 yrs; placebo 69 yrs
Smoking pack-yrs:
erythromycin 42; placebo 41
Comorbidity: N/Rb
FEV1 % predicted:
erythromycin 44%;
placebo 42%
Exacerbations in
previous yr: N/R
Erythromycin 125 mg
three times/day
(n Z 18) vs placebo
(n Z 18)
6 months  Significant reduction in
neutrophil counts in sputum
for erythromycin vs
placebo (P Z 0.05)
 Reduction in exacerbation
rate for erythromycin vs placebo
(RR 0.554; P Z 0.042)
 Erythromycin delayed the
time to first exacerbation vs
placebo (P Z 0.032)
Two erythromycin
patients discontinued
(abdominal pain
and heart failure
complications)
No resistance
reported
Albert et al.45 Randomised,
double-blind,
controlled trial
Mean age: azithromycin
65 yrs; placebo 66 yrs
Current smokers:
azithromycin 21%; placebo 23%
Comorbidity: N/Rb
FEV1: FVC %: azithromycin
42%; placebo 43%
Exacerbations in
previous yr: N/R
Azithromycin 250 mg/day
(n Z 570) vs placebo
(n Z 572)
12 months  Azithromycin reduced the
median time to exacerbation
(266 vs 174 days; P < 0.001)
 Reduced frequency of
exacerbations for azithromycin
(1.48 vs 1.83/pt yr; P Z 0.01)
 Significantly improved QoL
for azithromycin patients
(P Z 0.004)
Hearing decrements
more common in
azithromycin arm
(25% vs. 20%;
p Z 0.04).
Increased resistance
to macrolides in
the azithromycin
group (81% vs 41%;
p < 0.0001)
Pomares
et al.85
Retrospective,
uncontrolled
study
Mean age: 71 yrs
Current smokers: 0%
Chronic bronchitis: 24%
FEV1 % predicted: 32%
Exacerbations in
previous yr: 7.0
Azithromycin 500 mg
three times/week (n Z 24)
12 Months  Significant reduction
in exacerbations for
azithromycin vs baseline
(2.8 vs 6.8; P < 0.001),
hospitalisations (1.4 vs 3.6;
P < 0.001), and days in
hospital (25 vs 44; P Z 0.01)
 Exacerbations reduced
by 43% and hospitalisations
by 47% in pts colonised
by P. aeruginosa.
No clinically
significant AEs
observed
One H. influenzae
and four
S. pneumoniae
isolates developed
azithromycin
resistance
(continued on next page)
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Table 2 (continued )
Study Study design Patient characteristics
at baseline (mean)
Treatment Duration of
antibiotic
treatment
Outcom Side effects
Continuous therapy
Intermittent/pulsed therapy
Sethi et al.46 Randomised,
double-blind,
controlled trial
Mean age: moxifloxacin
66 yrs; placebo 66 yrs
Current smokers: moxifloxacin
35%; placebo 31%
Comorbidity: N/Rb
FEV1 % predicted: moxifloxacin
40%; placebo 41%
Exacerbations in previous yr:
moxifloxacin 2.6; placebo 2.6
Moxifloxacin 400 mg/day
(n Z 573) vs placebo
(n Z 584)
6  5-day treatments
every 8 weeks
48 week treatment;
24 week follow-up
 Odds suffering an
exace tion at 48 weeks
was re ced by 25% with
moxifl acin (PP population)
and 45 in pts with
purule /mucopurulent
sputum t baseline
 Signifi t difference
in fav of moxifloxacin
in the RQ symptom
domai 8.8 vs 4.4;
P Z 0 6).
More
treatment-emergent,
drug related AEs
with moxifloxacin
vs placebo
(p < 0.001), mainly
due to GI events
(4.7% vs 0.7%).
No evidence of
relevant resistance
development
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GI, gastrointestinal; QoL, quality of life; AEs, adverse events; PP, p protocol; SGRQ, St George’s Respiratory Question-
naire; SC, standard care; CAD, coronary artery disease; HTN, hypertension; MRC, Medical Research Council Dyspnoea Scale; TNFa, tum r necrosis factor-a; IL-6, interleukin-6; RR, relative
risk; N/R, not reported.
a Patients with bronchiectasis or diffuse pan-bronchiolitis were excluded.
b Patients with comorbid asthma, bronchiectasis or uncontrolled cardiac disease were excluded.
c Patients with an infective exacerbation with in the previous 6 weeks were excluded.
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Antibiotics for treatment and prevention of AE-COPD 507exacerbation-free interval.46,55,88 Pulsed therapy with
moxifloxacin was found to significantly reduce the risk of
an exacerbation by 25% (per protocol population) in pa-
tients with moderate-to-severe COPD, while in a post-hoc
analysis, this reduction was 45% in patients with puru-
lent/mucopurulent sputum at randomisation.46
These studies suggest that long-term antibiotic treat-
ment in COPD patients reduces exacerbation frequency,
though evidence for a reduction in inflammation is limited.
Long-term antibiotic therapy appears to be well tolerated,
though not all studies reported safety.81 Nevertheless,
gastrointestinal events were more common in patients
receiving pulsed moxifloxacin versus placebo (4.7% vs
0.7%, respectively)46 and 12-month azithromycin treatment
resulted in a higher incidence of hearing loss (25% of pa-
tients with azithromycin vs 20% of patients with placebo).45
Although long-term (daily) azithromycin treatment led to a
decrease in the incidence of colonisation by respiratory
pathogens, such treatment was also associated with an
increased prevalence of macrolide-resistant bacteria colo-
nising the airways, though there was no evidence that
this colonisation increased the number of exacerbations
or the incidence of pneumonia.45 No relevant resistance
was reported in the study with pulsed (with one cycle last-
ing for only 5 days in every 8 weeks) moxifloxacin treat-
ment,46 while in others resistance development was
minimal85,86 or not reported.81,82
Although the studies described above suggest that use of
prophylactic oral antibiotic therapy is well tolerated, some
macrolides are known to be proarrhythmic and even 5-day
treatment with azithromycin has been associated with a
small absolute increase in cardiovascular deaths.89 This
issue, coupled with concerns of increased antibiotic resis-
tance, indicates that such treatment should be reserved
for those with severe COPD who experience frequent exac-
erbations requiring multiple antibiotic treatments, in spite
of adequate management of their COPD with standard
treatments.90
Future directions: the role of inhaled
antibiotics in patients with COPD
Use of inhaled antibiotics is expected to have a future role
in the long-term management of patients with COPD since
this route of administration has the ability to target drug
delivery directly to respiratory tract. Such targeting reduces
systemic exposure and maximizes pharmacodynamic param-
eters, thereby also likely reducing the emergence of
antibiotic resistance and minimizing the development of
systemic adverse effects. Inhaled antibiotics have already
been used in the treatment of other respiratory tract
conditions, including cystic fibrosis (CF)67,68 and bronchiec-
tasis.91,92 Administration of aerosolised antibiotics plays a
particularly important role in CF, since patients with the
condition suffer from diminished mucociliary clearance,
increasing their susceptibility to colonisation and infection
by bacterial pathogens, including P. aeruginosa.93 In this
population, intermittent inhaled tobramycin has been
shown to improve pulmonary function and decrease
the density of P. aeruginosa in sputum, leading to significant
reductions in respiratory hospitalisations.67,68 Inhaledgentamycin has recently been shown to have a beneficial ef-
fect on outcomes in bronchiectasis, reducing the number of
exacerbations and decreasing P. aeruginosa in the sputum.72
In addition, use of inhaled dry powder ciprofloxacin in bron-
chiectasis patients has been associated with improved qual-
ity of life, which is likely to be due to reductions in bacterial
load and improved eradication (of approximately 35%).91
Inhaled antibiotics appear to be well tolerated in most
of the above studies, reducing the risks of adverse effects
associated with systemic exposure. While wheezing and
localised irritation (e.g. cough, bronchospasm) have been
reported in some studies,92,94,95 most report minimal side
effects.67,68,91 Choice of antimicrobial is dependent on
pharmacokinetics/pharmacodynamics in the bronchopul-
monary tree, with the ability to achieve high Cmax values fa-
vouring concentration-killing drugs, while the applied
delivery system influences particle size distribution and
hence deposition and exposure.96,97 Although the optimal
dosing regimen (e.g. continuous or pulsed) for inhaled anti-
biotics in COPD has not been determined, their administra-
tion in aerosolised form has the ability to achieve high,
microbiologically relevant concentrations in respiratory se-
cretions in excess of the MIC of the infecting organism(s).98
In COPD patients with chronic bacterial infection, delivery
of a high concentration of antibiotic in the airway through
inhalation may lead to a reduction in chronic inflammation
via a reduction in bacterial load, potentially reducing the
frequency of exacerbations. Nevertheless, evidence for a
reduction in airway inflammation following the use of aero-
solised antibiotics is limited.
The pharmacodynamic/pharmacokinetic profile of
inhaled antibiotic therapy in the lower respiratory tract
are quite different from systemic antibiotic use. The
measured concentrations of various antibiotics (gentamy-
cin, sisomycin, amikacin, tobramycin) in various locations
in the respiratory tract following inhalation exceeded the
highest MICs of the prevalent pathogens by between 50 and
125 times.99e105 In the presence of such high concentration
of antibiotics the density of pathogens was reduced in the
sputum or the pathogens were completely eradicated
(Table 3).67,91,106e116 However, adequate delivery of antibi-
otic to the airways through inhalation is a complex method
influenced by several factors. Conditions that have to be
optimised include the choice of nebuliser (jet or ultrasonic,
vibrating mesh inhaler), the drug formulation (aerosolised
solution or dry powder), the particle size (must be between
1 mm and 5 mm for adequate deposition and delivery into
lower airways), the chemical properties of the molecule
(e.g. lipophilic or hydrophilic). Furthermore, patient char-
acteristics including age and lung function, the respiratory
cycle length and inspiratory/expiratory ratio, may also in-
fluence efficiency of inhaled antibiotic delivery.
As seen with long-term systemic antibiotic use, concern
exists too for inhaled antibiotics regarding the possibility of
resistance development during long-term treatment. As
shown in Table 3, there is inconsistent evidence for the
emergence of resistant pathogens during treatment with
aerosolised antibiotics in some respiratory conditions67,95
(Table 3). It is likely that risk of resistance development
may be lessened by use of shorter courses, intermittent
therapy (as currently practiced in cystic fibrosis) or alter-
nating different antibiotic classes.
Table 3 Studies investigating resistance development during therapy with inhaled antibiotics.
Study Study design Indication Treatment Duration of therapy Secondary outcome on
resistance development
during or after therapy
and/or bacteriological outcome
Ramsey et al.67 Randomised, double-blind,
placebo-controlled,
multicentre trial
CF Tobramycin 300 mg bid
(n Z 258, PARI LC
Plus) vs placebo (n Z 262)
28 days therapy with
28 days run-off
period, 3 cycles
Decreased density of
P. aeruginosa in sputum
and increased % of
P. aeruginosa isolates
with MIC8 mg/L at the
end of the study (14.3%
of patients)
Lenoir et al.106 Randomised, double-blind,
placebo-controlled,
multicentre trial
CF Tobramycin 300 mg bid
(n Z 29, Pari LC
Plus) vs placebo (n Z 30)
28 days with 28 days
follow-up period, 1 cycle
No changes in MIC90
were observed up to
EOT with sputum
concentration of
tobramycin remaining
above the MIC throughout
the treatment; twice as
many patients in the
tobramycin group as in
the placebo group achieved
bacterial eradication at EOT
Chuchalin et al.107 Randomised, double-blind,
placebo-controlled,
multicentre trial
CF Tobramycin 300 mg bid
(n Z 161, Pari LC
Plus) vs placebo (n Z 84)
28 days on- and 28
days off-therapy, 3 cycles
MIC90 for mucoid strains of
P. aeruginosa increased
from 6.6 mg/L to 18.2 mg/L
and the % of resistant
P. aeruginosa strains
increased from 9.7% to 23.6%
by the end of the study in the
tobramycin group; no MIC
changes were seen in placebo
group; bacteriological
eradication was achieved
by EOT in twice as many
tobramycin-treated patients
as in placebo-treated patients
McCoy et al.108 Randomised, double-blind,
placebo-controlled,
multicentre trial
CF Aztreonam (AZLI) 75 mg bid
(n Z 69) vs placebo (n Z 66)
28 Days with 56 days
follow-up, 1 cycle
MIC90 transiently increased
4-fold in AZLI-treated patients
for P. aeruginosa and returned
after treatment has finished,
P. aeruginosa density
decreased in sputum
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Palmer et a.109 Randomised, double-blind,
placebo-controlled,
single-centre trial
Ventilator-associated
tracheobronchitis in
hospitalised patients
Vancomycin, 120 mg,
tid and/or Gentamycin,
80 mg, tid (n Z 19,
pathogen-targeted therapy
using AeroTech II nebuliser) vs
placebo (n Z 24)
14 Days treatment
with 14 days follow-up
period
There was no resistance
development with aerosolised
antibiotics (vancomycin or
gentamycin) by EOT and
bacterial growth was
reduced in purulent
tracheobronchial secretions
Hansen et al.110 Retrospective cohort
observational study
CF Inhaled colistin (1 mio. or
2 mio, bid or tid) þ PO
ciprofloxacin (10e20 mg/kg/day)
Since diagnosis 15
years follow up of
patients
Longer interval without
P. aeruginosa in sputum
compared with non-treated
CF patients
No colistin resistance was
found among all P. aeruginosa
isolates
Retsch-Bogart
et al.111
Randomised, double-blind,
placebo-controlled,
multicentre trial
CF Aztreonam (AZLI) 75 mg
tid (n Z 80) vs placebo (n Z 84)
28 Days with 14
days follow-up,
1 cycle
MIC90 transiently increased
4-fold in AZLI-treated
patients for P. aeruginosa,
without increases in drug
concentration in sputum,
and returned by day 42;
P. aeruginosa density decreased
in sputum
Oermann et al.112 Open label, not
controlled study
CF Aztreonam (AZLI) 75 mg tid
(n Z 189) or 75 mg bid
(n Z 85), PARI eFlow
18 Months of alternating
28 days on-therapy and
28 days off-therapy
P. aeruginosa MIC50 and MIC90
transiently increased during
the study4-fold during bid
and tid administration in
20% and 30% of patients,
respectively
Konstan et al.113 Randomised, open-label,
placebo-controlled,
multicentre study
CF Tobramycin 112 mg bid
(n Z 46 using T-326
Inhaler) vs placebo (n Z 49),
28 Days therapy with
28 days run-off, 3 cycles
Decreased density of
P. aeruginosa in sputum
and increased % of patients
with MICs8 mg/L for
P. aeruginosa by the end
of the study
Konstan et al.114 Randomised, open-label,
multicentre, two-arm study
CF Tobramycin 112 mg bid
(n Z 308, via T-326 Inhaler)
or tobramycin 300 mg bid
(n Z 209, via PARI LC Plus)
28 Days therapy with
28 days run-off period,
3 cycles
Decreased density of
P. aeruginosa in sputum,
and increased % of patients
with MICs8 mg/L for P. aeruginosa
by the end of the study
Wainwright et al.115 Randomised, double-blind,
placebo-controlled,
multicentre trial
CF Aztreonam (AZLI) 75 mg tid
(n Z 76) vs placebo (n Z 81)
28 Days with 14
days follow-up,
1 cycle
Decreased density of
P. aeruginosa in sputum,
increased MIC50 and MIC90
in AZLI-treated patients
and increased % of patients
with MICs8 mg/L for
P. aeruginosa by the end of the study
(continued on next page)
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Table 3 (continued )
Study Study design Indication Treatment Duration of therapy Secondary outcome on
resistance development
during or after therapy
and/or bacteriological outcome
Wilson et al.91 Randomised, double-blind,
placebo-controlled,
multicentre trial
NCFB Ciprofloxacin dry powder
inhalation 32.5 mg bid
(n Z 60) vs placebo (n Z 64)
28 Days with 56
days follow-up
Pseudomonas aeruginosa,
S. maltophilia, H. influenzae
MICs transiently increased
in six subjects by EOT and
MIC decreased by day 56
in the ciprofloxacin dry powder
inhalation group, with a
decrease in density of pathogens
in sputum, in addition 35% of
patients in ciprofloxacin
dry powder inhalation
group vs 8% of patients in
placebo group achieved
bacterial eradication at EOT
Clancy et al.116 Randomised, double-blind,
placebo-controlled,
multicentre trial
CF Amikacin liposomal
aerosol, 70 mg,
140 mg, 280 mg,
560 mg qd (n Z 69)
vs placebo (n Z 36)
28 Days with
28 days run-off,
up to 6 cycles
Decreased density of
P. aeruginosa in sputum with
highest dose and no significant
changes in MIC50 and in MIC90
for P. aeruginosa during treatment
CF, cystic fibrosis; NCFB, non-cystic fibrosis bronchiectasis; qd, once daily; bid, twice daily; tid, three times daily; MIC, minimum inhibitory concentration (mg/L); EOT, end-of-therapy;
PO, per os.
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Antibiotics for treatment and prevention of AE-COPD 511To date, there have been only two published reports
investigating the use of inhaled antibiotics in patients with
COPD. Dal Negro et al.117 examined the impacts of 14-day,
twice daily treatment with inhaled tobramycin nebuliser so-
lution on clinical outcome as well as inflammatory markers
in bronchial secretions from a small cohort (nZ 13) of mul-
tiresistant P. aeruginosa-colonised patients with severe
COPD (FEV1 < 50% predicted). P. aeruginosa infection is
associated with a severe degree of functional impairment
in COPD,118 and colonisation could well herald the presence
of bronchiectasis,41,119 suggesting a potential role for
inhaled antibiotics. Indeed, such treatment resulted in a
substantial reduction from baseline of pro-inflammatory
chemotactic mediators, including interleukin-1 beta
(P < 0.03), interleukin-8 (P < 0.02) and eosinophilic cationic
protein (P < 0.01). After the 6-month follow-up period, P.
aeruginosa was considered to be eradicated in two patients,
while P. aeruginosa density was reduced in a further four pa-
tients. Two-week treatment with inhaled tobramycin
decreased the frequency of exacerbations by 42%, when
compared with the 6-month period prior to initiating inhaled
tobramycin therapy.117 Although this study has many limita-
tions, including its open-label design and its small size, it
does suggest a therapeutic role for inhaled antibiotics in
COPD patients, particularly those colonised with multiresist-
ant P. aeruginosa. Nevertheless, a recent phase II study
investigating the efficacy of MP-376 (levofloxacin inhaled so-
lution) in COPD patients at high risk for exacerbations
(n Z 322) failed to demonstrate a significant reduction in
the exacerbation rate or an increase in the time to the
next exacerbation compared with placebo.120 However,
the treatment duration employed in this study (5 days every
28 days for 9e12 cycles) may have been suboptimal in a pop-
ulation of patients with chronic infection.121 Ongoing and
future trials will inform us if inhaled antibiotics are a useful
therapeutic option in the prevention of exacerbations of
COPD.Conclusions
Acute, efficacious antibiotic treatment is the mainstay in
the management of patients with severe COPD and symp-
tomatic exacerbations that include at least 2 of the 3
cardinal symptoms (increased sputum purulence, volume
and increased dyspnoea; Anthonisen type I or II exacerba-
tions). Although such treatment is associated with clinical
benefit, treatment failure and relapse rates may be high in
patients with the frequent exacerbator phenotype. Failure
may be related to inadequate antibiotic efficacy through
incomplete resolution of the initial exacerbation and
persistent bacterial infection.23e26 These factors have led
to recommendations for a stratified approach to antibiotic
therapy based on patient risk factors.15 Patients at greatest
risk for poorer outcome (i.e. those with complicated COPD)
are likely to derive greatest benefit from early treatment
with the most potent antibiotic therapy, such as amoxi-
cillin/clavulanate and respiratory fluoroquinolones which
have a broad spectrum of activity against likely patho-
gens.28,122e124 The use of the most efficacious antibiotics
in patients with risk factors may be crucial in preventing re-
lapses or delaying subsequent exacerbations which appearto cluster in time, and if the exacerbation is poorly
controlled there is a high risk of the next episode occurring
within a few weeks.30 A significant relationship exists be-
tween bacterial eradication at the end of antibiotic treat-
ment and no relapse in the following eight weeks.28
Studies conducted in the last 20 years suggest that long-
term or intermittent antibiotic therapy may have a bene-
ficial effect on the outcome of COPD patients and may
improve quality of life by reducing exacerbation frequency
and hospitalisations for exacerbations, or by extending
time to next exacerbation. The mechanisms underlying
such improvements are unclear. It is possible that the
benefit of long-term antibiotic treatment may be due to a
reduction in the frequency of exacerbations due to erad-
ication of colonising potentially pathogenic bacteria and/or
reduction in chronic airway inflammation,37 though the ev-
idence supporting such a hypothesis is limited. While mac-
rolides are known to have both antibacterial and anti-
inflammatory effects, it is unknown to what degree these
actions are responsible for their efficacy when used for
the treatment of chronic respiratory conditions. The
increased rate of nasopharyngeal colonisation by pathogens
resistant to macrolides seen following long-term azithromy-
cin therapy45 suggests that emergence of antibiotic resis-
tance is likely with this approach.
Although systemic antibiotics are likely to remain the
primary treatment option for patients with moderate-to-
severe COPD, inhaled antibiotics may provide a more
appropriate way for the treatment and prevention of
exacerbations in the future, particularly for the frequent
exacerbators with chronic bacterial infection and for those
with radiologically confirmed bronchiectasis. Regardless of
the route of administration, however, further studies are
required to estimate the potential risks of antibiotic pro-
phylaxis in terms of long-term adverse events and resis-
tance development and to assess whether benefit
outweighs the potential risks.Conflicts of interest
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